Pin42 Cost-Effectiveness of Switching Strategies From a 7-Valentto a 13-Valent Pneumococcal Conjugate Vaccine

Claes, Christa; Mittendorf, Thomas; Kuchenbecker, U; Rose, M; Rr, Reinert

doi:10.1016/s1098-3015(10)75100-7

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Unclassified

Year Published

2009

2016

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ante la disponibilidad de la PCV-10 y la PCV-13, se han llevado a cabo evaluaciones económicas en diversos contextos nacionales, tales como Holanda [37], Grecia [38], Alemania [39], Canadá [40], Reino Unido [41] y México [16].…”

Section: Discussionunclassified

Evaluación Económica de un Programa de Inmunización Infantil en México Basado en la Vacuna Neumocócica Conjugada 13-Valente

et al. 2011

View full text Add to dashboard Cite

show abstract

Section: Discussionunclassified

Evaluación Económica de un Programa de Inmunización Infantil en México Basado en la Vacuna Neumocócica Conjugada 13-Valente

et al. 2011

View full text Add to dashboard Cite

show abstract

Gesundheitsökonomische Modellierung eines Szenarios zum Serotypen-Catch-up bei der Impfung gegen Pneumokokken mit PCV13 (Prevenar 13®) in Deutschland

Claes

Schulenburg

2010

Pharmacoeconomics-Ger-Res-Articles

View full text Add to dashboard Cite

Interchangeability between Pneumococcal Conjugate Vaccines: A Systematic Review and Meta-Analysis

Ciapponi

Alison

Bardach

et al. 2016

Value in Health Regional Issues

View full text Add to dashboard Cite

There was no direct comparative information available on the interchangeability among PCVs, but they have pretty similar immunogenicity and safety. PCV10 versus PCV13 cost-effectiveness varied according to price, indirect effects, and indirect costs. PCV10 gains more quality-adjusted life-years because of the prevention of more frequent yet less severe events such as otitis media, and PCV13 prevents less frequent but more costly events such as invasive diseases.

show abstract

Pin42 Cost-Effectiveness of Switching Strategies From a 7-Valentto a 13-Valent Pneumococcal Conjugate Vaccine

Cited by 4 publications

References 0 publications

Evaluación Económica de un Programa de Inmunización Infantil en México Basado en la Vacuna Neumocócica Conjugada 13-Valente

Evaluación Económica de un Programa de Inmunización Infantil en México Basado en la Vacuna Neumocócica Conjugada 13-Valente

Gesundheitsökonomische Modellierung eines Szenarios zum Serotypen-Catch-up bei der Impfung gegen Pneumokokken mit PCV13 (Prevenar 13®) in Deutschland

Interchangeability between Pneumococcal Conjugate Vaccines: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About